Ascletis Pharma (ASCLF) News Today $1.22 0.00 (0.00%) As of 10/3/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock ASCLF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Ascletis Pharma Inc. (OTCMKTS:ASCLF) Short Interest Down 99.3% in SeptemberOctober 1, 2025 | americanbankingnews.comAscletis Pharma Grants 650,000 Share Options to EmployeesSeptember 30, 2025 | tipranks.comAscletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide ...September 23, 2025 | uk.finance.yahoo.comAscletis Pharma trial shows drug candidate ASC47 boosts weight loss effect of semaglutideSeptember 23, 2025 | finance.yahoo.comAscletis Pharma’s ASC47 Shows Promising Results in Obesity TreatmentSeptember 21, 2025 | tipranks.comAscletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide MonotherapySeptember 21, 2025 | prnewswire.comAscletis Pharma Reports Successful Phase III Trial Results for Acne TreatmentSeptember 17, 2025 | msn.comAscletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of ...September 17, 2025 | finance.yahoo.comAscletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025September 17, 2025 | prnewswire.comAscletis ASC30 GLP 1R Data 2025 Oral Obesity Drug Cuts Weight Twelve Per CentSeptember 17, 2025 | msn.comAscletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the ...September 16, 2025 | finance.yahoo.comAscletis Pharma Reports Promising Phase Ib Results for Obesity TreatmentSeptember 16, 2025 | msn.comAscletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual MeetingSeptember 16, 2025 | prnewswire.comAscletis Pharma’s Controlling Shareholders Commit to Share Lock-Up Amid Clinical TrialsSeptember 11, 2025 | tipranks.comAscletis’ GLP-1RA shows promise with quarterly dosing scheduleSeptember 11, 2025 | msn.comAscletis Pharma (SEHK:1672) Reports Promising Data For ASC30 Obesity Treatment In U.S. TrialsSeptember 11, 2025 | finance.yahoo.comAscletis Pharma’s ASC30 Shows Promise in Obesity ManagementSeptember 9, 2025 | tipranks.comAscletis Announces Ultra-Long-Acting Subcutaneous Depot Maintenance Formulation of Small Molecule GLP-1R Agonist ASC30 Demonstrated an Observed Half-Life of 75 Days in Participants with ObesitySeptember 9, 2025 | prnewswire.comAscletis Pharma to Present Promising ASC30 Study Results at EASD MeetingSeptember 2, 2025 | tipranks.comAscletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual MeetingSeptember 2, 2025 | prnewswire.comAscletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose StudyAugust 27, 2025 | prnewswire.comAscletis Reports Stronger Weight Loss Results With Dual Agonist ComboAugust 18, 2025 | msn.comAscletis Pharma’s Obesity Drug Candidates Show Promising Preclinical ResultsAugust 17, 2025 | tipranks.comAscletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of ObesityAugust 17, 2025 | prnewswire.comAscletis Unveils ASC47 Weight Loss Drug CandidateAugust 13, 2025 | msn.comAscletis Pharma’s ASC47 Shows Superior Efficacy in Obesity TreatmentAugust 13, 2025 | msn.comAscletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical ModelAugust 12, 2025 | prnewswire.comAscletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or OverweightAugust 5, 2025 | prnewswire.comAscletis Begins Dosing in U S Phase IIa Study for Monthly GLP 1R Obesity DrugJuly 28, 2025 | msn.comAscletis Pharma Begins Phase IIa Study of ASC30 for Obesity TreatmentJuly 27, 2025 | tipranks.comAscletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30July 27, 2025 | prnewswire.comAscletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of ObesityJuly 14, 2025 | prnewswire.comAscletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30July 2, 2025 | prnewswire.comAscletis Pharma Faces Patent Challenge from CSPC SubsidiaryJune 29, 2025 | tipranks.comAscletis Pharma Begins U.S. Phase I Trial for Psoriasis Drug ASC50June 17, 2025 | tipranks.comAscletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of PsoriasisJune 17, 2025 | prnewswire.comAscletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)June 8, 2025 | prnewswire.comAscletis Pharma to Present Promising Obesity Treatments at ADA Scientific SessionsJune 8, 2025 | tipranks.comAscletis’s daily acne tablet set for China review after Phase III winJune 5, 2025 | msn.comAscletis Pharma’s Denifanstat Achieves Breakthrough in Acne TreatmentJune 3, 2025 | tipranks.comAscletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All EndpointsJune 3, 2025 | prnewswire.comAscletis Faces Import Ban and Sanction in ITC RulingMay 30, 2025 | tipranks.comAscletis Pharma Secures FDA Clearance for Psoriasis Drug TrialMay 22, 2025 | tipranks.comAscletis Announces U.S. FDA Clearance of IND Application for Its Oral Small Molecule IL-17 Inhibitor, ASC50, for the Treatment of PsoriasisMay 22, 2025 | prnewswire.comAscletis Pharma Inc. Announces Successful AGM with Key Resolutions PassedMay 22, 2025 | tipranks.comAscletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of ObesityMay 20, 2025 | prnewswire.comAscletis to Present ASC47 Weight Loss Drug at European CongressMay 6, 2025 | tipranks.comAscletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on ObesityMay 6, 2025 | prnewswire.comAscletis Reports Positive U S Phase Ib Results for ASC30 Submits Phase IIa Protocol to FDAApril 23, 2025 | msn.comAscletis Pharma Reports Positive Phase Ib Results for ASC30 in Obesity TreatmentApril 22, 2025 | tipranks.com Get Ascletis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASCLF Media Mentions By Week ASCLF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASCLF News Sentiment▼1.190.54▲Average Medical News Sentiment ASCLF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASCLF Articles This Week▼31▲ASCLF Articles Average Week Get the Latest News and Ratings for ASCLF and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ascletis Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies 60 Degrees Pharmaceuticals News Today Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Ascentage Pharma Group International News Today Avacta Group News Today Awakn Life Sciences News Today BerGenBio ASA News Today BriaCell Therapeutics News Today CARsgen Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ASCLF) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascletis Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascletis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
